Primary |
Product Used For Unknown Indication |
21.8% |
Hepatic Cirrhosis |
14.5% |
Drug Use For Unknown Indication |
12.2% |
Hypoalbuminaemia |
8.0% |
Ascites |
6.5% |
Ischaemic Stroke |
4.6% |
Hypertension |
4.2% |
Peritonitis Bacterial |
3.8% |
Haemorrhagic Disorder |
3.1% |
Hepatic Function Abnormal |
2.3% |
Immunosuppression |
2.3% |
Iron Deficiency Anaemia |
2.3% |
Sedation |
2.3% |
Septic Shock |
2.3% |
Coagulopathy |
1.9% |
Hepatic Encephalopathy |
1.9% |
Cirrhosis Alcoholic |
1.5% |
Fluid Replacement |
1.5% |
Generalised Oedema |
1.5% |
Haemolytic Uraemic Syndrome |
1.5% |
|
Tremor |
16.7% |
Hepatitis C |
10.0% |
Pulmonary Oedema |
9.2% |
Sepsis |
7.5% |
Feeling Abnormal |
5.8% |
Respiratory Distress |
5.8% |
Pyrexia |
5.0% |
Brain Oedema |
4.2% |
Transfusion-related Acute Lung Injury |
4.2% |
Hepatitis B |
3.3% |
Malaise |
3.3% |
Pleural Effusion |
3.3% |
Transmission Of An Infectious Agent Via A Medicinal Product |
3.3% |
Urticaria |
3.3% |
Dermatitis Exfoliative |
2.5% |
Erythema |
2.5% |
Hepatitis C Rna Positive |
2.5% |
Infusion Related Reaction |
2.5% |
Medication Error |
2.5% |
Respiratory Arrest |
2.5% |
|
Secondary |
Product Used For Unknown Indication |
23.9% |
Psoriatic Arthropathy |
12.1% |
Drug Use For Unknown Indication |
11.8% |
Prophylaxis |
10.5% |
Hypertension |
4.9% |
Ascites |
3.8% |
Hepatic Cirrhosis |
3.2% |
Hypoalbuminaemia |
3.2% |
Antipyresis |
2.8% |
Iron Deficiency Anaemia |
2.8% |
Infection |
2.7% |
Insomnia |
2.7% |
Cholestasis |
2.2% |
Drug Therapy |
2.1% |
Constipation |
2.0% |
Hepatorenal Syndrome |
2.0% |
Hypovolaemic Shock |
2.0% |
Nutritional Support |
2.0% |
Hepatitis C |
1.9% |
Convulsion Prophylaxis |
1.7% |
|
Hepatitis C |
15.9% |
Erythema |
13.4% |
Dermatitis Exfoliative |
9.6% |
Tremor |
9.6% |
Histiocytosis Haematophagic |
6.4% |
Transmission Of An Infectious Agent Via A Medicinal Product |
5.7% |
Stevens-johnson Syndrome |
5.1% |
Thrombotic Microangiopathy |
4.5% |
Toxic Epidermal Necrolysis |
4.5% |
Infection |
3.2% |
Liver Disorder |
3.2% |
Feeling Abnormal |
2.5% |
Pulmonary Congestion |
2.5% |
Tumour Lysis Syndrome |
2.5% |
Blood Pressure Decreased |
1.9% |
Bronchospasm |
1.9% |
Hepatitis B |
1.9% |
Hepatitis B Surface Antigen Positive |
1.9% |
Pruritus |
1.9% |
Rash |
1.9% |
|
Concomitant |
Product Used For Unknown Indication |
36.7% |
Drug Use For Unknown Indication |
19.1% |
Prophylaxis |
6.9% |
Sedation |
3.7% |
Fluid Replacement |
3.7% |
Infection |
3.3% |
Hypertension |
2.7% |
Coronary Artery Bypass |
2.6% |
Infection Prophylaxis |
2.4% |
Ureteral Stent Insertion |
2.4% |
Ureteral Stent Removal |
2.4% |
Surgery |
1.8% |
Pyrexia |
1.8% |
Insomnia |
1.7% |
Diuretic Therapy |
1.7% |
Abdominal Pain |
1.6% |
Hypoalbuminaemia |
1.5% |
Pain |
1.5% |
Prophylaxis Against Graft Versus Host Disease |
1.3% |
Anticoagulant Therapy |
1.2% |
|
Sepsis |
8.7% |
Respiratory Failure |
8.6% |
Renal Failure |
8.5% |
Injury |
7.7% |
Unevaluable Event |
7.6% |
Pain |
7.4% |
White Blood Cell Count Decreased |
6.2% |
Thrombocytopenia |
5.1% |
Vomiting |
5.0% |
Anxiety |
4.9% |
Fear |
4.6% |
Renal Failure Acute |
4.3% |
Anhedonia |
3.8% |
Septic Shock |
3.5% |
Emotional Distress |
2.7% |
Pneumonia |
2.6% |
Renal Impairment |
2.6% |
Depression |
2.3% |
Multi-organ Failure |
2.0% |
Staphylococcal Sepsis |
1.9% |
|